灵康药业：关于“灵康转债”预计满足转股价格修正条件的提示性公告

Core Viewpoint - Lingkang Pharmaceutical announced that its stock price has been below 85% of the current conversion price for 10 trading days, indicating a potential trigger for downward adjustment of the conversion price as per the prospectus [2] Group 1 - The stock price has been below the conversion price of 5.53 yuan per share for the specified period [2] - The company will convene a board meeting on the triggering date to decide whether to adjust the conversion price and will fulfill its information disclosure obligations promptly [2]